• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by TransCode Therapeutics Inc. (Amendment)

    2/14/24 4:00:27 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNAZ alert in real time by email
    SC 13G/A 1 rnaz117242sc13ga1.htm AMENDMENT NO. 1

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

     

    SCHEDULE 13G/A

     

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    TransCode Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

     

     

    89357L204

    (CUSIP Number)

     

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    oRule 13d-1(b)

     

    xRule 13d-1(c)

     

    oRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 8 pages 
     

     

    CUSIP No. 89357L204

     

    13G/A Page 2 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Partners, LP

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) x

    3 SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

    Number of

    Shares

    BENEFICIALLY

    Owned by

    Each Reporting

    Person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0%

    12

    type of reporting person

     

    pN

     

     Page 2 of 8 pages 
     

     

    CUSIP No. 89357L204

     

    13G/A Page 3 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) x

    3 SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

    Number of

    Shares

    BENEFICIALLY

    Owned by

    Each Reporting

    Person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0%

    12

    type of reporting person

     

    OO

     

     Page 3 of 8 pages 
     

     

    CUSIP No. 89357L204

     

    13G/A Page 4 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

    2 Check the Appropriate Box if a Member of a Group*

    (a) o

    (b) x

    3 SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    united states

    Number of

    Shares

    BENEFICIALLY

    Owned by

    Each Reporting

    Person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0%

    12

    type of reporting person

     

    IN

     

     Page 4 of 8 pages 
     

     

    Item 1(a).Name of Issuer:

     

    TransCode Therapeutics, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    6 Liberty Square, #2382, Boston, MA 02109

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 89357L204

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 pages 
     

     

    (b)Percent of Class:

     

    Tang Capital Partners 0.0%
    Tang Capital Management 0.0%
    Kevin Tang 0.0%

     

    (c) Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

     Page 6 of 8 pages 
     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 14, 2024  
         
         
    TANG CAPITAL PARTNERS, LP  
         
    By:  Tang Capital Management, LLC, its General Partner  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    TANG CAPITAL MANAGEMENT, LLC  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8 pages

     

     

     

    Get the next $RNAZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNAZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RNAZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

    BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, in collaboration with Quantum Leap Healthcare Collaborative (Quantum Leap), today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application amendment for a planned Phase 2a clinical trial with TransCode's lead therapeutic candidate, TTX-MC138. The study will be conducted by Quantum Leap within their PRE-I-SPY program, a leading platform for innovative oncology clinical trials, and represents the program's first exp

    2/5/26 8:04:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

    TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injectionTTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive glioblastoma modelsStudy supports future clinical development of TTX-MC138 for patients with glioblastomaBOSTON, Jan. 6, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the publication of preclinical research supporting the application of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM). The article was publi

    1/6/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Fitzgerald Thomas A bought $25,168 worth of shares (49,350 units at $0.51), increasing direct ownership by 708% to 56,318 units (SEC Form 4)

    4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

    10/2/23 4:39:08 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dudley Robert Michael bought $49,980 worth of shares (98,000 units at $0.51), increasing direct ownership by 119% to 180,262 units (SEC Form 4)

    4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

    10/2/23 4:37:49 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAZ
    SEC Filings

    View All

    TransCode Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    2/5/26 8:10:42 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by TransCode Therapeutics Inc.

    SCHEDULE 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

    1/7/26 12:38:49 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    1/6/26 8:04:38 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Czerepak Elizabeth

    3 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

    12/22/25 4:39:46 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Stover Jack E

    3 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

    12/22/25 4:39:09 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Marquet Magda

    4 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

    6/18/24 4:16:51 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAZ
    Leadership Updates

    Live Leadership Updates

    View All

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

    RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncologyDr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and commercialized the first FDA-approved RNAi drugBOSTON, May 28, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, Ph.D., to its Scientific Advisory Board. Dr. Zamore is a prominent biotechnology innovator known for his pioneering work in RNA interference (RNAi). Together with world-renowned scientists, including  Nobel Laureate, Dr Phillip

    5/28/25 8:00:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAZ
    Financials

    Live finance-specific insights

    View All

    TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company

    TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life SciencesConcurrent equity investment of $25 Million from CK Life Sciences into TransCodeTransCode expands its microRNA-based pipeline with Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanomaPhilippe Calais, PharmD, PhD, becomes Chief Executive Officer and remains Chairman of the Board. Tom Fitzgerald, MBA, remains Chief Financial Officer. Elizabeth Czerepak, MBA, appointed as a new independent Board Member and Chairperson of the Audit CommitteeBOSTON and SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (

    10/8/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Acquires Option for Radiotheranostic Technology

    BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer.

    5/19/22 9:00:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TransCode Therapeutics Inc.

    SC 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

    11/6/24 4:05:33 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by TransCode Therapeutics Inc.

    SC 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

    7/26/24 4:05:13 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by TransCode Therapeutics Inc.

    SC 13D - Transcode Therapeutics, Inc. (0001829635) (Subject)

    6/21/24 4:02:06 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care